Evidence map›Paper›PMID 37513875›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

The Glutaminase-1 Inhibitor [

Yiding Zhang, Katsushi Kumata, Lin Xie, Yusuke Kurihara, Masanao Ogawa, Tomomi Kokufuta, Nobuki Nengaki, Ming-Rong Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Efficient one-pot radiosynthesis of theEJNMMI radiopharmacy and chemistry · 2025
    Article
  4. The N-acetyltransferase 10 inhibitor [EJNMMI radiopharmacy and chemistry · 2025
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yiding ZhangDepartment of Advanced Nuclear Medicine Sciences, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Katsushi KumataDepartment of Advanced Nuclear Medicine Sciences, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Lin XieDepartment of Advanced Nuclear Medicine Sciences, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.ORCID 0000-0002-6472-322X
Yusuke KuriharaDepartment of Advanced Nuclear Medicine Sciences, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Masanao OgawaDepartment of Advanced Nuclear Medicine Sciences, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Tomomi KokufutaDepartment of Advanced Nuclear Medicine Sciences, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Nobuki NengakiDepartment of Advanced Nuclear Medicine Sciences, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Ming-Rong ZhangDepartment of Advanced Nuclear Medicine Sciences, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
National Institutes for Quantum Science and Technology · JPJapan Proton Accelerator Research Complex · JP

Funding

Japan Society for the Promotion of Science B-23H02867Moonshot Research and Development Program No. 21zf0127003h001
6 · The paper itself

Abstract

Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) is a selective inhibitor of glutaminase-1 (GLS1), consequently inhibiting glutaminolysis. BPTES is known for its potent antitumor activity and plays a significant role in senescent cell removal. In this study, we synthesized [

Indexed as

[11C]acylation[11C-carbonyl]BPTESglutaminase-1 (GLS1)glutaminase-1 inhibitorPETsenescence

Identifiers

PMID37513875
PMCPMC10384602
OpenAlexW4383345857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.